Hemispherx Biopharma Inc. (AMEX: HEB) Files New Drug Application with the FDA
Hemispherx Biopharma announced today that it has filed a new drug application with the U.S. Food and Drug Administration for its experimental therapeutic which is designed to treat Chronic Fatigue Syndrome. The company also announced that it is moving forward with filings in other countries. Chronic Fatigue Syndrome could be affecting more than 1 million people in the U.S. and causing an economic impact of more than $9 billion dollars every year. The Centers for Disease Control (CDC) claims that Chronic Fatigue Syndrome is “as disabling as other severe chronic conditions like multiple sclerosis, Chronic Obstructive Pulmonary Disease and rheumatoid arthritis.…